Pramipexole

Instructions for Pramipexole

Common name: Pramipexole
Trade name: Pramipexole
All names: Pramipexole, Pramipexole, Mirapa, Pramipexole, MIRA PEX, MIRAPEXIN, SIFROL, DAQUIRAN, Trivastal, Sifrol

Indications:
Pramipexole is mainly used to treat Parkinson's disease and its syndromes. Can be used alone or in combination with levodopa

Usage and dosage:
In the first week, take 0.125 mg orally, 3 times a day, and in the 2nd week, take 0.250 mg orally, 3 times a day; thereafter increase by 0.750 mg every week, up to a maximum of 4.5 mg per day

Adverse reactions:
The most common adverse reaction is dyskinesia. Constipation, nausea, and dyskinesia often resolve gradually with treatment.
Hypotension may occur in the early stages of treatment, especially when the dosage of this product is increased too quickly.

Taboos:
Not allowed for breast-feeding patients.
Those allergic to pramipexole or any other ingredients in the product.

Precautions:
When patients with renal impairment take this product, reduce the dose. Hallucinations are side effects of dopaminergic receptor agonists and levodopa therapy. Patients should be informed that hallucinations (mostly visual) may occur. In advanced Parkinson's disease, combined use of levodopa may cause dyskinesia during the initial dose increase of this product. If the above side effects occur, the dosage of levodopa should be reduced.
This product has been associated with drowsiness and sudden sleep attacks, especially in people with Parkinson's disease. Sudden sleep attacks during daily activities, sometimes without awareness or warning, but are rarely reported. Patients must be informed of this side effect and advised to drive vehicles or operate machinery with caution during treatment with this product.
Patients who have experienced the side effects of drowsiness and/or sudden sleep attacks must avoid driving or operating machinery, and a dose reduction or discontinuation of treatment should be considered.
Due to possible additive effects, patients should be cautious when using other sedative drugs or alcohol while taking pramipexole.
Patients with psychiatric disorders should be treated only with dopaminergic agonists if the potential benefits outweigh the risks. Concomitant use of pramipexole with antipsychotics should be avoided.
Eye examinations should be performed regularly or when visual abnormalities occur.
Attention should be paid to patients with concomitant severe cardiovascular disease. Because dopaminergic therapy is associated with the development of orthostatic hypotension, monitoring of blood pressure is recommended, especially during the initial stages of treatment.
Symptoms of non-neurostatic malignant syndrome have been reported when dopaminergic therapy is abruptly discontinued.

Storage:
Sealed, below 30℃

Mechanism of action:
Pramipexole is a non-ergot dopamine agonist. In vitro studies have shown that pramipexole has high specificity for D2 receptors and full intrinsic activity, and its affinity for D3 receptors is higher than that of D2 and D4 receptors. The relevance of this binding of pramipexole to D3 receptors for Parkinson's disease is unclear. The exact mechanism by which pramipexole treats Parkinson's disease is unknown, but is currently thought to be related to activation of dopamine receptors in the striatum. Animal electrophysiological experiments show that pramipexole can affect the firing frequency of striatal neurons by activating dopamine receptors in the striatum and substantia nigra.

Safety and efficacy:
To analyze the therapeutic effect of pramipexole on Parkinson's disease. 60 patients with Parkinson's disease were selected as research subjects, and the patients were randomly divided into an observation group and a control group. Patients in the control group were given conventional Parkinson's treatment drugs, while the observation group was given pramipexole medication based on the control group. Results: The total effective rate of the observation group was higher than that of the control group; the difference was significant (P<0.05); the incidence of adverse reactions in the observation group was lower than that of the control group, but there was no significant difference (P<0.05). Conclusion: The use of pramipexole in the treatment of Parkinson's disease can significantly improve the patient's therapeutic effect without increasing the incidence of complications.